N
ORIC icon

Nuveen’s Oric Pharmaceuticals ORIC Stock Holding History

Nuveen’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.94M Buy
153,022
+8,619
+6% +$97.8K ﹤0.01% 2292
2025
Q4 		$1.18M Buy
144,403
+6,711
+5% +$77.3K ﹤0.01% 2544
2025
Q3 		$1.65M Buy
137,692
+15,006
+12% +$158K ﹤0.01% 2376
2025
Q2 		$1.25M Sell
122,686
-44,816
-27% -$301K ﹤0.01% 2510
2025
Q1 		$935K Hold
167,502
– – ﹤0.01% 2668
2024
Q4 		$1.35M Hold
167,502
– – ﹤0.01% 2560
2024
Q3 		$1.72M Buy
167,502
+1,309
+0.8% +$12.9K ﹤0.01% 2492
2024
Q2 		$1.17M Buy
166,193
+30,406
+22% +$272K ﹤0.01% 2653
2024
Q1 		$1.87M Hold
135,787
– – ﹤0.01% 2437
2023
Q4 		$1.25M Sell
135,787
-33,232
-20% -$240K ﹤0.01% 2627
2023
Q3 		$1.02M Hold
169,019
– – ﹤0.01% 2562
2023
Q2 		$1.31M Buy
+169,019
New +$960K ﹤0.01% 2534
2022
Q2 		– Sell
-112,748
Closed -$753K – 3423
2022
Q1 		$753K Buy
112,748
+1,589
+1% +$14.3K ﹤0.01% 2905
2021
Q4 		$1.31M Sell
111,159
-8,058
-7% -$126K ﹤0.01% 2754
2021
Q3 		$3.01M Buy
119,217
+4,019
+3% +$81.5K ﹤0.01% 2483
2021
Q2 		$2.04M Buy
115,198
+42,000
+57% +$920K ﹤0.01% 2704
2021
Q1 		$1.79M Buy
73,198
+5,202
+8% +$164K ﹤0.01% 2667
2020
Q4 		$2.3M Buy
67,996
+34,152
+101% +$980K ﹤0.01% 2436
2020
Q3 		$846K Buy
33,844
+151
+0.4% +$3.59K ﹤0.01% 2754
2020
Q2 		$1.14M Buy
+33,693
New +$1.08M ﹤0.01% 2573

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Nuveen's ORIC Position: Q1 2026 in Review

Nuveen increased its Oric Pharmaceuticals (ORIC) stake by 6% in Q1 2026, buying an estimated $97.8K and bringing the position to 153,022 shares worth $1.94M. The position accounts for ﹤0.01% of the portfolio, ranked #2292.

Nuveen first reported a position in ORIC in Q2 2020 and has held it in 20 quarters since. The position peaked at $3.01M in Q3 2021. 182 funds tracked by Wall St. Rank hold ORIC as of Q1 2026.

  • Nuveen held 153,022 shares of Oric Pharmaceuticals worth $1.94M as of Q1 2026.
  • Nuveen bought 8,619 Oric Pharmaceuticals shares in Q1 2026, an estimated $97.8K.
  • Oric Pharmaceuticals made up ﹤0.01% of Nuveen's portfolio in Q1 2026, its #2292 holding.
  • Nuveen first reported a position in Oric Pharmaceuticals in Q2 2020 and has held it in 20 quarters since.
  • Nuveen's Oric Pharmaceuticals position peaked at $3.01M in Q3 2021.
  • 182 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.